Nicotine Gum Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (2mg, 4mg, 6mg), By Distribution Channel (Supermarkets And Hypermarkets, Pharmaceuticals, Online Channels), And By Geography - Forecasts From 2023 To 2028

  • Published : Feb 2023
  • Report Code : KSI061614362
  • Pages : 135

Nicotine gum is a smoking cessation aid accessible over the counter (OTC). It pursues to support those who are habituated to tobacco to decrease their cigarette consumption and eventually break the habit of smoking.

Chewing the gum releases nicotine, which is then taken up by the mouth's lining and absorbed into circulation. This aids in progressively lessening nicotine cravings, withdrawal symptoms, and the yearning to smoke. It is frequently obtainable in three different strengths, 2 mg, 4 mg, and 6 mg, contingent on the quantity of nicotine it comprises. Individuals’ usage renders to how many cigarettes they smoke each day. One of the foremost factors fueling the market's expansion is the upsurge in the case of lung cancer and other respiratory diseases. Smoking is recognized to be a contributory influence to a numeral of chronic conditions, including coronary heart disease (CHD), oropharyngeal cancer, esophageal cancer, stroke, rheumatoid arthritis, TB, and several immune-related illnesses.

Rising health consciousness and increased knowledge of these illnesses are mutually driving the market's expansion. An additional feature that endorses expansion is the increasing use of smoking cessation treatments. Abundant administrations and non-governmental organizations (NGOs) in established and emerging countries are reassuring the usage of smoking cessation aids like nicotine gums to support people, specifically young people, who are addicted to tobacco. Supplementary aspects are anticipated to fuel the industry, such as numerous product expansions like the formation of rising urbanization, nicotine lozenges, and substantial research and development efforts.

Promotions for the anti-smoking movement to aid market development

People who want to break the habit of smoking can take nicotine gum every two hours to gratify their cravings. It is predicted that increased R&D will upsurge product demand, as will government and non-government organizations' advertising of the product. Furthermore, manufacturers encourage anti-smoking efforts and introduce cutting-edge matters like lozenges and gum to ward off the necessity to smoke. Furthermore, it is estimated that increased rates of smoking-related illnesses including lung cancer boost product demand. These fundamentals spur the market for nicotine gum to enlarge.

However, market expansion in the subsequent years is estimated to be constrained by nicotine gum's adverse effects.

An increasing number of people trying to quit smoking can be a major growth factor

People who desire to stop smoking are experimenting with a diversity of smoking cessation aids, including e-cigarettes. Abundant universal public responsiveness initiatives and campaigns aim to persuade the public to give up smoking. For instance, on May 31 every year "World No Tobacco Day" is entitled by the World Health Organization (WHO). Such initiatives increase public consciousness of the undesirable effects of smoking on one's health and encourage the acceptance of sensible measures to curtail tobacco use. The "Campaign for Tobacco-Free Kids" encourages individuals to quit smoking and lessens tobacco's terrible toll on a global scale. Throughout the forecast period, a numeral amount of these awareness campaigns are anticipated to fuel market expansion.

North America is projected to be the prominent market shareholder in the nicotine gum market and is anticipated to continue throughout the forecast period.

Because of government programs and campaigns, there has been an immense growth in the proportion of health-conscious customers in North America, which has in return supported the industry's expansion here. Major brands are as well present in the area, and they are concentrating on emerging new products to encounter the market's mounting demand for nicotine gums. For instance, Nicorette lately presented a smoother-textured nicotine gum product enclosed ice mint lozenge. These essentials are predicted to fuel market expansion over the forecast period. The major part of the market for nicotine gum here is measured by the United States.

Due to increasing sales of nicotine products in nations like Germany, the United Kingdom, France, Italy, etc. Europe also holds a generous portion of the market. Furthermore, the provincial administration is emphasizing the employment of smoking cessation methods profoundly.

However, Asia Pacific is projected to experience dissolute CAGR growth over the analysis period owing to the increasing customer demand for additional developed products, amplified rivalry amongst tobacco companies, and growing commercial opportunities. Japan is anticipated to endure to be the area with the sturdiest progress over the forecasting period. It is estimated that the firm anti-smoking laws passed in China and India will lift demand for substitute items like nicotine gums.

Market Key Developments

  • In February 2022, The first generic nicotine chewing gum, sold under the trade name Nicotine beta, has been introduced to the German market by Enorama Pharma's business partner, beta pharm Arzneimittel GmbH. Nicotine Beta will promote the benefits of NRT with a generic medication (Nicotine Replacement Therapy).
  • In July 2021, Fertin Pharma, a producer, and developer of health and pharmaceutical products using intra-oral and oral delivery technologies was purchased by Philip Morris International.

Nicotine Gum Market Scope:


Report Metric Details
 Growth Rate  CAGR during the forecast period
 Base Year  2021
 Forecast Period  2023–2028
 Forecast Unit (Value)  USD Billion
 Segments Covered  Type, Distribution Channel, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered GlaxoSmithKline Plc, Johnson and Johnson, Novartis Consumer Health, ITC Limited, Cipla Health Limited, Perrigo Company Plc, Fertin Pharma, Alchem International, Revolymer
 Customization Scope  Free report customization with purchase



  • By Type
    • 2mg
    • 4mg
    • 6mg
  • By Distribution Channel
    • Supermarkets and Hypermarkets
    • Pharmaceuticals
    • Online Channels
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • UK
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Taiwan
      • Thailand
      • Indonesia
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline



2.1. Research Data

2.2. Assumptions



3.1. Research Highlights



4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis



5.1. Introduction

5.2. 2mg

5.3. 4mg

5.4. 6mg



6.1. Introduction

6.2. Supermarkets and Hypermarkets

6.3. Pharmaceuticals

6.4. Online channels



7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Others

7.5. The Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Israel

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. South Korea

7.6.5. Indonesia

7.6.6. Thailand

7.6.7. Others



8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix



9.1. GlaxoSmithKline Plc

9.2. Johnson and Johnson

9.3. Novartis Consumer Health

9.4. ITC Limited

9.5. Cipla Health Limited

9.6. Perrigo Company Plc

9.7. Fertin Pharma

9.8. Alchem International

9.9. Revolymer

GlaxoSmithKline Plc

Johnson and Johnson

Novartis Consumer Health

ITC Limited

Cipla Health Limited

Perrigo Company Plc

Fertin Pharma

Alchem International